AQP4 and synovial sarcoma: The prevalence of SS is greater among AQP4-IgG-positive patients than among AQP4-IgG-negative patients, with a potential prevalence of 10–20% at the time of diagnosis of AQP4-IgG-positive NMOSD (41).